Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS‑addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC‑6236), a RAS(ON) multi‑selective inhibitor; elironrasib (RMC‑6291), a RAS(ON) G12C‑selective inhibitor; zoldonrasib (RMC‑9805), a RAS(ON) G12D‑selective inhibitor; and RMC‑5127, a RAS(ON) G12V‑selective inhibitor, are currently in clinical development.
The Manager, FP&A Europe will support the Sr Director FP&A Europe in driving financial planning, reporting, business analytics, and operational execution across the European region as the company prepares for commercial growth.
Based in Basel, Switzerland, this role will coordinate budgeting and forecasting activities, deliver financial insights, support reporting and planning tools, a...